Seelos Therapeutics Inc (SEEL)
0.92
-0.11
(-10.68%)
USD |
OTCM |
Nov 04, 16:00
Seelos Therapeutics Free Cash Flow: -13.27M for June 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2024 | -13.27M |
| March 31, 2024 | -18.21M |
| December 31, 2023 | -23.91M |
| September 30, 2023 | -35.09M |
| June 30, 2023 | -40.42M |
| March 31, 2023 | -54.91M |
| December 31, 2022 | -61.60M |
| September 30, 2022 | -66.85M |
| June 30, 2022 | -66.29M |
| March 31, 2022 | -54.79M |
| December 31, 2021 | -49.00M |
| September 30, 2021 | -33.98M |
| June 30, 2021 | -27.66M |
| March 31, 2021 | -25.74M |
| December 31, 2020 | -20.91M |
| September 30, 2020 | -22.70M |
| June 30, 2020 | -21.43M |
| March 31, 2020 | -17.79M |
| December 31, 2019 | -19.30M |
| September 30, 2019 | -21.13M |
| June 30, 2019 | -15.54M |
| March 31, 2019 | -14.14M |
| December 31, 2018 | -8.129M |
| September 30, 2018 | -3.657M |
| June 30, 2018 | -9.369M |
| Date | Value |
|---|---|
| March 31, 2018 | -9.698M |
| December 31, 2017 | -10.47M |
| September 30, 2017 | -10.70M |
| June 30, 2017 | -8.531M |
| March 31, 2017 | -9.499M |
| December 31, 2016 | -13.09M |
| September 30, 2016 | -11.81M |
| June 30, 2016 | -17.57M |
| March 31, 2016 | -22.96M |
| December 31, 2015 | -22.98M |
| September 30, 2015 | -30.75M |
| June 30, 2015 | -28.27M |
| March 31, 2015 | -24.34M |
| December 31, 2014 | -18.60M |
| September 30, 2014 | -8.844M |
| June 30, 2014 | -8.909M |
| March 31, 2014 | -9.376M |
| December 31, 2013 | -15.64M |
| September 30, 2013 | -19.34M |
| June 30, 2013 | -18.03M |
| March 31, 2013 | -16.45M |
| December 31, 2012 | -14.82M |
| September 30, 2012 | -14.16M |
| June 30, 2012 | -14.07M |
| March 31, 2012 | -12.72M |
Free Cash Flow Range, Past 5 Years
-66.85M
Minimum
Sep 2022
-13.27M
Maximum
Jun 2024
-35.47M
Average
-27.66M
Median
Jun 2021
Free Cash Flow Benchmarks
| 180 Life Sciences Corp | -4.242M |
| Cassava Sciences Inc | -86.31M |
| Cara Therapeutics Inc | -83.33M |
| Citius Pharmaceuticals Inc | -29.09M |
| Moleculin Biotech Inc | -25.75M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -0.972M |
| Cash from Financing (Quarterly) | 0.742M |
| Free Cash Flow Per Share (Quarterly) | -6.183 |
| Free Cash Flow Yield | -16.42K% |